Aktas I, Nazikoglu C, Kepez A, Ozkan F U, Kaysin M Y, Akpinar P, Dogan Z, Ileri C, Saymaz S, Erdogan O
Physical Therapy and Rehabilitation Clinic, Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey.
Family Medicine Clinic, Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey.
Osteoporos Int. 2016 Dec;27(12):3543-3547. doi: 10.1007/s00198-016-3684-6. Epub 2016 Jun 25.
We evaluated the effects of zoledronic acid (ZA) therapy on electrocardiographic (ECG) parameters for the first time in the literature. Measurements were performed on ECGs obtained before and after ZA infusion on the same day as well as 1 month after the infusion. ZA infusion did not have any short- or long-term effect on any parameter that might be associated with the tendency for atrial fibrillation or ventricular arrhythmias.
The aim of the present study was to evaluate the early and late effects of ZA therapy on ECG parameters which might be associated with the tendency for atrial and ventricular arrhythmias.
Consecutive patients with osteoporosis who were admitted to our clinic between December 2013 and December 2014 and who were scheduled to receive ZA infusion constituted our study population. Twelve-lead surface ECGs were obtained from all patients before and after ZA infusion on the same day as well as 1 month after the infusion. All ECG parameters were measured and compared with each other for each patient.
Data of 100 patients were used in the analysis (9 male; 70.5 ± 11.6 years of age). There were no significant differences between repeated measurements regarding pmax, pmin, and p dispersion values. QT max and QT min values were significantly increased after infusion; however, there were no significant changes in QT dispersion, Tp-e interval, and Tp-e dispersion values.
ZA infusion did not affect P wave dispersion both at the immediate post-infusion period and 1 month after infusion. QT values were significantly increased early after ZA infusion; however, there were no significant differences in parameters reflecting disparity of ventricular recovery times and transmural dispersion of ventricular repolarization. Based on these observations, it may be suggested that ZA infusion did not have any short- or long-term effect on any parameter that might be associated with the tendency for atrial fibrillation or ventricular arrhythmias.
我们首次在文献中评估了唑来膦酸（ZA）治疗对心电图（ECG）参数的影响。在ZA输注当天以及输注后1个月，对同一日输注ZA前后所获得的心电图进行测量。ZA输注对任何可能与房颤或室性心律失常倾向相关的参数均无短期或长期影响。
本研究的目的是评估ZA治疗对可能与房性和室性心律失常倾向相关的ECG参数的早期和晚期影响。
2013年12月至2014年12月期间入住我们诊所且计划接受ZA输注的连续性骨质疏松患者构成了我们的研究人群。在ZA输注当天以及输注后1个月，从所有患者获取12导联体表心电图。对每位患者的所有ECG参数进行测量并相互比较。
100例患者的数据用于分析（9例男性；年龄70.5±11.6岁）。关于pmax、pmin和p离散度值的重复测量之间无显著差异。输注后QT max和QT min值显著增加；然而，QT离散度、Tp-e间期和Tp-e离散度值无显著变化。
ZA输注在输注后即刻及输注后1个月均不影响P波离散度。ZA输注后早期QT值显著增加；然而，反映心室复极时间差异和心室复极跨壁离散度的参数无显著差异。基于这些观察结果，可提示ZA输注对任何可能与房颤或室性心律失常倾向相关的参数均无短期或长期影响。
